Sputnik V will be produced in 100 million doses in India
the
The Russian Fund for Direct Investment (RDIF) and Indian pharmaceutical company Hetero have agreed to produce more than 100 million doses of the Sputnik V Covid-19 vaccine annually on Indian soil.
Production is expected to begin early next year, the RDIF, which funded the development of the Russian vaccine, said in a statement.
RDIF chief Kirill Dmitriev said the agreement "will provide the Indian people with an efficient solution in this difficult period of the pandemic." He added that Sputnik V should become "an integral part of each country's national vaccine portfolio".
RDIF and Hetero, one of India's leading generic pharmaceutical companies, agree to produce over 100 million doses of the #SputnikV vaccine in India
Read more: https://t.co/bJL0Yg60CL
– Sputnik V (@sputnikvaccine) November 27, 2020
In August, Russia became the first country to register a Covid-19 vaccine. On Tuesday, Russian officials said Sputnik V's effectiveness rate was 91.4 percent after a second dose was given to the volunteers.
A few days ago the Hungarian foreign minister announced that, following an agreement with a local pharmaceutical company, he will test the Russian vaccine.
Thanks to our Telegram channel you can stay updated on the publication of new articles of Economic Scenarios.
The article Sputnik V will be produced in 100 million doses in India comes from ScenariEconomici.it .
This is a machine translation of a post published on Scenari Economici at the URL https://scenarieconomici.it/sputnik-v-sara-prodotto-in-100-in-india-milioni-di-dosi/ on Fri, 27 Nov 2020 12:50:19 +0000.